Clinical Trials
임상시험 트래커
국내사는 전체 임상 이력, 글로벌 메이저는 진행 중 파이프라인을 추적합니다. ClinicalTrials.gov API v2에서 6시간 주기로 수집합니다.
기업
10 results
- 2/3상모집 중· Acute Myeloid Leukemia급성 골수성 백혈병 성인 환자에서 피벡키맙 수니린, 베네톡락스, 아자시티딘 병용 투여 시 이상반응 및 질병활동성 변화 평가 연구
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
리드: 애브비
- 2/3상모집 중· Diabetic Retinopathy당뇨병성 망막병증 환자에서 맥락막상부공간 투여 Surabgene Lomparvovec
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
리드: 애브비
- 2/3상모집 중· Metastatic Pancreatic Ductal Adenocarcinoma성인 1차 전이성 췌장도관선암종 환자를 대상으로 표준 치료와 비교한 정맥주사 텔리소투주맙 아디주테칸과 플루오로우라실, 폴린산, 옥살리플라틴(FOLFOX)의 병용 평가 연구
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
리드: 애브비
- 2/3상모집 중· Multiple MyelomaA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
리드: 애브비
- 2/3상모집 중· Non-Small Cell Lung CancerA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
리드: 애브비
- 2/3상모집 중· Non-Squamous Non-Small Cell Lung CancerA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
리드: 애브비
- 2/3상모집 중· Non-Small Cell Lung CancerStudy to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
리드: 애브비
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.